Literature DB >> 29045266

Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy.

David D Yang1, Vinayak Muralidhar2, Brandon A Mahal2, Clair J Beard1,3, Kent W Mouw1,3, Neil E Martin1,3, Peter F Orio1,3, Martin T King1,3, Paul L Nguyen1,3.   

Abstract

OBJECTIVES: Following radical prostatectomy (RP), adjuvant radiation therapy (RT) decreases biochemical recurrence and potentially improves metastasis-free and overall survival for patients with high-risk pathologic features. Since adjuvant RT typically occurs daily over several weeks, the logistical challenges of extensive traveling may be a significant barrier to its use. We examined the association between distance to treatment facility and use of adjuvant RT.
MATERIALS AND METHODS: We identified 97,568 patients in the National Cancer Database diagnosed from 2004 through 2011 with cT1-4N0-xM0-x prostate cancer and found to have high-risk pathologic features (pT3-4 stage and/or positive surgical margins) at RP. Multivariable logistic regression adjusting for sociodemographic and clinicopathologic factors was used to examine the association between travel distance and receipt of adjuvant RT, defined as radiotherapy initiated within 12 months after RP.
RESULTS: Overall, 10.6% (10,346) of the study cohort received adjuvant RT. On multivariable analysis, increasing travel distance was significantly associated with decreased use of adjuvant RT, with adjusted odds ratios of 1.0 (reference), 0.67, 0.46, 0.39, and 0.32 (all P<0.001) and prevalence of use at 12.6%, 8.8%, 6.3%, 4.9%, and 3.7% for patients living ≤25.0, 25.1 to 50.0, 50.1 to 75.0, 75.1 to 100.0, and >100.0 miles away, respectively.
CONCLUSIONS: Increasing travel distance was strongly associated with decreased use of adjuvant RT in this national cohort of postprostatectomy patients with high-risk pathologic features. These results strongly suggest that the logistical challenges of extensive travel are a significant barrier to the use of adjuvant RT. Efforts aimed at improving access to radiotherapy and reducing treatment time are urgently needed.

Entities:  

Mesh:

Year:  2018        PMID: 29045266     DOI: 10.1097/COC.0000000000000410

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  2 in total

1.  Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer.

Authors:  Leo Y Luo; Emeline M Aviki; Anna Lee; Marisa A Kollmeier; Nadeem R Abu-Rustum; C Jillian Tsai; Kaled M Alektiar
Journal:  Gynecol Oncol       Date:  2021-02-15       Impact factor: 5.482

2.  Overall survival based on oncologist density in the United States: A retrospective cohort study.

Authors:  Sudeep K Siddappa Malleshappa; Smith Giri; Smit Patel; Tapan Mehta; Leonard Appleman; Scott F Huntington; Vida Passero; Rahul A Parikh; Kathan D Mehta
Journal:  PLoS One       Date:  2021-05-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.